NO20085408L - Protease screeningmetoder og proteaser identifisert derved - Google Patents

Protease screeningmetoder og proteaser identifisert derved

Info

Publication number
NO20085408L
NO20085408L NO20085408A NO20085408A NO20085408L NO 20085408 L NO20085408 L NO 20085408L NO 20085408 A NO20085408 A NO 20085408A NO 20085408 A NO20085408 A NO 20085408A NO 20085408 L NO20085408 L NO 20085408L
Authority
NO
Norway
Prior art keywords
modified
proteases
screening methods
substrate
protease
Prior art date
Application number
NO20085408A
Other languages
English (en)
Norwegian (no)
Inventor
Edwin L Madison
Original Assignee
Torrey Pines Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrey Pines Inst filed Critical Torrey Pines Inst
Publication of NO20085408L publication Critical patent/NO20085408L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6408—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21109—Matriptase (3.4.21.109)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
NO20085408A 2006-07-05 2008-12-30 Protease screeningmetoder og proteaser identifisert derved NO20085408L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81891006P 2006-07-05 2006-07-05
US81880406P 2006-07-05 2006-07-05
PCT/US2007/015571 WO2008045148A2 (en) 2006-07-05 2007-07-05 Protease screening methods and proteases identified thereby

Publications (1)

Publication Number Publication Date
NO20085408L true NO20085408L (no) 2009-04-06

Family

ID=39217879

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085408A NO20085408L (no) 2006-07-05 2008-12-30 Protease screeningmetoder og proteaser identifisert derved

Country Status (18)

Country Link
US (3) US8211428B2 (es)
EP (4) EP2402437B1 (es)
JP (5) JP4546578B2 (es)
KR (5) KR101476458B1 (es)
CN (1) CN103289980A (es)
AT (1) ATE530644T1 (es)
AU (1) AU2007307260B2 (es)
CA (1) CA2656531C (es)
DK (1) DK2046951T5 (es)
ES (3) ES2721266T3 (es)
HK (3) HK1126521A1 (es)
IL (3) IL196314A0 (es)
MX (1) MX2008016221A (es)
NO (1) NO20085408L (es)
NZ (2) NZ596269A (es)
SG (2) SG175602A1 (es)
TW (2) TW201139677A (es)
WO (1) WO2008045148A2 (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US7939304B2 (en) * 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
JP5376747B2 (ja) * 2002-10-02 2013-12-25 カタリスト バイオサイエンシーズ， インコーポレイテッド 改変された特異性を有するプロテアーゼを作製する方法およびスクリーニングする方法
EP2308967B1 (en) * 2004-04-12 2017-08-23 Catalyst Biosciences, Inc. Mutant mt-sp1 polypeptides
CN101340928B (zh) 2005-10-21 2011-12-21 催化剂生物科学公司 抑制补体激活的修饰的蛋白酶
TW200804416A (en) * 2006-06-19 2008-01-16 Nautilus Technology Llc Modified coagulation factor IX polypeptides and use thereof for treatment
AU2007307260B2 (en) 2006-07-05 2013-02-28 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thereby
AU2008239586B2 (en) * 2007-04-13 2013-09-26 Catalyst Biosciences, Inc. Modified factor VII polypetides and uses thereof
US8501449B2 (en) 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
DK2853269T3 (da) 2008-05-19 2019-08-05 Advaxis Inc Dobbelt indgivelsessystem til heterologe antigener, der omfatter en rekombinant Listeria-stamme svækket ved mutation af dal/dat og deletion af ActA, der omfatter et nukleinsyremolekyle, der koder for et listeriolysin O-prostataspecifikt antigenfusionsprotein
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
MY178905A (en) * 2008-08-29 2020-10-22 Oral Health Australia Pty Ltd Prevention, treatment and diagnosis of p.gingivalis infection
FI121711B (fi) 2009-04-30 2011-03-15 Ab Enzymes Oy Sieniperäinen seriiniproteaasi ja sen käyttö
FI121712B (fi) 2009-04-30 2011-03-15 Ab Enzymes Oy Uusi sieniperäinen proteaasi ja sen käyttö
FI121851B (fi) 2009-07-08 2011-05-13 Ab Enzymes Oy Sieniperäinen proteaasi ja sen käyttö
US8652476B2 (en) * 2009-07-27 2014-02-18 Niigata University Pharmaceutical composition for treating ischemic events
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
EP2525814A4 (en) * 2010-01-22 2013-09-11 Univ Louisville Res Found METHODS OF TREATING OR PREVENTING PERIODONTITIS AND PARODONTIST-RELATED DISEASES
WO2011149272A2 (ko) * 2010-05-25 2011-12-01 주식회사 나노엔텍 단백질분해에 의하여 활성화되는 효소의 활성형의 정성적 및 정량적 분석방법
GB2482536B (en) 2010-08-05 2013-07-24 Hera Pharmaceuticals Inc Expression of antibody or a fragment thereof in lactobacillus
WO2012138377A2 (en) 2010-10-01 2012-10-11 Trustees Of The University Of Pennsylvania The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
FI123942B (fi) 2010-10-29 2013-12-31 Ab Enzymes Oy Sieniperäisen seriiniproteaasin variantteja
FR2966734B1 (fr) 2010-10-29 2014-07-18 Max Rombi Composition comprenant au moins une enzyme proteolytique pour son utilisation pour empecher la synthese des triglycerides
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
US8940297B2 (en) * 2010-12-22 2015-01-27 Saint Louis University Expression of thrombin variants
CN103687611A (zh) 2011-03-11 2014-03-26 阿德瓦希斯公司 基于李斯特菌属的佐剂
FI123425B (fi) 2011-03-31 2013-04-30 Ab Enzymes Oy Proteaasientsyymi ja sen käytöt
WO2013126587A1 (en) * 2012-02-21 2013-08-29 Cytonics Corporation Systems, compositions, and methods for transplantation
WO2013138337A1 (en) 2012-03-12 2013-09-19 Advaxis Suppressor cell function inhibition following listeria vaccine treatment
JP6363600B2 (ja) 2012-07-25 2018-07-25 カタリスト・バイオサイエンシーズ・インコーポレイテッドＣａｔａｌｙｓｔ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 修飾第ｘ因子ポリペプチドおよびその使用
AU2014225678B2 (en) * 2013-03-06 2016-11-17 Glaxosmithkline Llc Host cells and methods of use
CA2921287A1 (en) * 2013-07-03 2015-01-08 Research Foundation Of The City University Of New York Method for screening catalytic peptides using phage display technology
WO2015031654A2 (en) 2013-08-28 2015-03-05 Cytonics Corporation Systems, compositions, and methods for transplantation and treating conditions
GB201322091D0 (en) * 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
EP2886140A1 (en) * 2013-12-17 2015-06-24 University of Limerick An apparatus for the extracorporeal treatment of blood
US20170165230A1 (en) 2014-04-09 2017-06-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
GB2536650A (en) 2015-03-24 2016-09-28 Augmedics Ltd Method and system for combining video-based and optic-based augmented reality in a near eye display
BR112017028052A2 (pt) * 2015-06-23 2018-09-11 Epivax Inc peptídeo, método para induzir uma resposta imune em um sujeito e formulação de vacina
EP3121272A1 (en) * 2015-07-24 2017-01-25 Zymetech ehf. Novel fish trypsin isoforms and their use
KR102622462B1 (ko) * 2016-01-18 2024-01-08 주식회사 엘지생활건강 신경세포 투과 촉진 활성의 펩타이드
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
DE102016204814A1 (de) * 2016-03-23 2017-09-28 Henkel Ag & Co. Kgaa Verbesserte Reinigungsleistung an Protein sensitiven Anschmutzungen
DE102016204815A1 (de) * 2016-03-23 2017-09-28 Henkel Ag & Co. Kgaa Proteasen mit verbesserte Enzymstabilität in Waschmittel
EP3466444A4 (en) * 2016-06-02 2019-12-11 Riken ADJUVANT COMPOSITION AND USE THEREOF
TW202323287A (zh) 2016-11-28 2023-06-16 日商中外製藥股份有限公司 包含抗原結合域與運送部分的多胜肽
IL271587B2 (en) 2017-06-22 2024-05-01 Catalyst Biosciences Inc Modified membrane-type serine protease 1 polypeptides (MTSP-1) and methods of use
WO2019028507A1 (en) * 2017-08-08 2019-02-14 Queensland University Of Technology METHODS OF DIAGNOSING PRECOCUS STAGES OF CARDIAC INSUFFICIENCY
JP7140362B2 (ja) * 2018-04-09 2022-09-21 国立大学法人東海国立大学機構 活性型組換えアクロシン
EP3787543A4 (en) 2018-05-02 2022-01-19 Augmedics Ltd. REGISTRATION OF A REFERENCE MARK FOR AN AUGMENTED REALITY SYSTEM
KR102131300B1 (ko) * 2018-05-02 2020-07-07 한국과학기술연구원 세균에서 단량체 ｃａｒｄ를 생산하는 방법
CN111088242A (zh) * 2018-10-23 2020-05-01 北京谱峰源生物科技有限公司 Ctss蛋白及编码其的基因的用途
US11766296B2 (en) 2018-11-26 2023-09-26 Augmedics Ltd. Tracking system for image-guided surgery
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
PE20211664A1 (es) 2018-12-28 2021-08-26 Catalyst Biosciences Inc Polipeptidos de activador de plasminogeno, tipo urocinasa, modificados y metodos de uso
WO2020168061A1 (en) * 2019-02-13 2020-08-20 Biomadison, Inc. Compositions and methods for protease screening
CN110079514A (zh) * 2019-04-12 2019-08-02 江苏大学 一种制备蛋白酶3重组蛋白的方法
EP3981428A4 (en) * 2019-06-05 2023-07-12 Chugai Seiyaku Kabushiki Kaisha PROTEAS SUBSTRATE AND POLYPEPTIDE WITH PROTEAS CLEAVAGE SEQUENCE
KR102174197B1 (ko) * 2019-06-12 2020-11-04 주식회사 앤씨비아이티 생산성이 향상된 비독성 프로테아제
US11980506B2 (en) 2019-07-29 2024-05-14 Augmedics Ltd. Fiducial marker
WO2021028577A1 (en) 2019-08-14 2021-02-18 Universität Innsbruck Bacterial selection system for target-specific proteases
EP3833381B1 (en) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration
CN110878313A (zh) * 2019-12-21 2020-03-13 吉林大学 大豆Gm-SEIPIN2家族基因及其在提高植物种子含油量中的应用
US11382712B2 (en) 2019-12-22 2022-07-12 Augmedics Ltd. Mirroring in image guided surgery
CN111004794B (zh) * 2019-12-30 2022-07-22 江南大学 一种热稳定性提高的枯草蛋白酶e突变体及其应用
WO2021199037A1 (en) * 2020-03-29 2021-10-07 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of determining activity of activated protein c
CN111534603B (zh) * 2020-04-23 2022-07-26 中国检验检疫科学研究院 一种利用荧光rpa鉴定白纹伊蚊的方法
CN111621511B (zh) * 2020-05-25 2022-04-08 中国科学院深圳先进技术研究院 多蛋白体系的共生产方法、多蛋白体系的循环共生产系统及应用
CN111718923B (zh) * 2020-06-30 2022-09-27 北京联合大学 一种用于治疗白菜软腐病的药物的筛选方法
US20220033383A1 (en) 2020-07-20 2022-02-03 Enanta Pharmaceuticals, Inc. Functionalized peptides as antiviral agents
WO2022031733A2 (en) * 2020-08-03 2022-02-10 Cornell University Keratinolytic polypeptides and methods of use
BR112023003606A2 (pt) 2020-08-28 2023-03-28 Codexis Inc Protease recombinante, composição, sequência polinucleotídica recombinante, vetor de expressão, célula hospedeira, métodos para produzir uma protease recombinante e para tratar e/ou prevenir os sintomas de insuficiência pancreática, e, uso
KR20230074194A (ko) * 2020-09-21 2023-05-26 바이엘 크롭사이언스 엘피 신규 세린 프로테아제
US11352363B1 (en) 2020-11-23 2022-06-07 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11384090B2 (en) 2020-11-23 2022-07-12 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
MX2023005983A (es) 2020-11-23 2023-08-15 Enanta Pharm Inc Nuevos agentes antivirales derivados de la espiropirrolidina.
CN112662694A (zh) * 2020-12-25 2021-04-16 康九生物科技(长春)有限公司 一种麦芽糖结合蛋白、麦芽糖结合蛋白表达载体、重组工程菌及其应用
US11970502B2 (en) 2021-05-04 2024-04-30 Enanta Pharmaceuticals, Inc. Macrocyclic antiviral agents
US11319325B1 (en) 2021-05-11 2022-05-03 Enanta Pharmaceuticals, Inc. Macrocyclic spiropyrrolidine derived antiviral agents
US11896445B2 (en) 2021-07-07 2024-02-13 Augmedics Ltd. Iliac pin and adapter
US11339170B1 (en) 2021-07-23 2022-05-24 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11325916B1 (en) 2021-07-29 2022-05-10 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
CN113999866B (zh) * 2021-11-04 2023-09-05 南京农业大学 一种高密度展示的噬菌粒载体及其用途
WO2023086400A1 (en) 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
WO2023086352A1 (en) 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US11858945B2 (en) 2021-11-12 2024-01-02 Enanta Pharmaceuticals, Inc. Alkyne-containing antiviral agents
WO2023144412A1 (en) * 2022-01-31 2023-08-03 Aarhus Universitet A biopharmaceutical prodrug platform based on protein conformational change
CN115260314B (zh) * 2022-05-10 2023-10-24 吉林大学 一种重组嗜热中性蛋白酶及其在降解蛋白质中的应用
CN116426509A (zh) * 2023-04-27 2023-07-14 上海佶凯星生物科技有限公司 一种碱性蛋白酶组合突变体及其应用

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3847770A (en) 1972-04-10 1974-11-12 Continental Can Co Photopolymerizable compositions prepared from beta hydroxy esters and polyitaconates
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1541435A (en) 1975-02-04 1979-02-28 Searle & Co Immunological materials
US4046784A (en) 1975-04-04 1977-09-06 Texaco Development Corporation Boride catalyst for epoxidizing olefinic compounds
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4460561A (en) 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4468457A (en) 1981-06-01 1984-08-28 David M. Goldenberg Method for producing a CSAp tryptic peptide and anti-CSAp antibodies
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
FI88932C (fi) 1982-04-15 1993-07-26 Genentech Inc Framstaellning av funktionellt maenskligt urokinasprotein
US4818709A (en) 1983-01-21 1989-04-04 Primus Frederick J CEA-family antigens, Anti-CEA antibodies and CEA immunoassay
US4460459A (en) 1983-02-16 1984-07-17 Anschutz Mining Corporation Sequential flotation of sulfide ores
US4624846A (en) 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
EP0238473A3 (en) 1986-03-18 1989-06-07 Monsanto Company Serine protease inhibitors
US4687610A (en) 1986-04-30 1987-08-18 E. I. Du Pont De Neumours And Company Low crystallinity polyester yarn produced at ultra high spinning speeds
EP0266032A1 (en) * 1986-08-29 1988-05-04 Beecham Group Plc Modified fibrinolytic enzyme
FI100106B (fi) 1986-12-05 1997-09-30 Novartis Ag Menetelmä plasminogeenin yksisäikeisen yhdistelmäaktivaattorin valmist amiseksi
US4932412A (en) 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
GB8721023D0 (en) 1987-09-07 1987-10-14 Lepetit Spa Modified plasminogen activators
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5541297A (en) 1988-04-01 1996-07-30 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
EP0336508A1 (en) * 1988-04-06 1989-10-11 K.U. Leuven Research & Development Recombinant human single-chain urokinase-type plasminogen activator mutant produced by site-specific mutagenesis of lysine 158 to histidine 158
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JP3771253B2 (ja) 1988-09-02 2006-04-26 ダイアックス コープ． 新規な結合タンパク質の生成と選択
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5304482A (en) 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
DE69034013T2 (de) 1989-03-06 2003-07-31 Univ Texas Serpin-resistenter T-PA; Mutanten; Gene
US5866413A (en) 1989-03-06 1999-02-02 Board Of Regents Of The University Of Texas System Pai-1 mutants
US5550042A (en) 1989-03-06 1996-08-27 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors and genes encoding the same and serine protease inhibitor mutants and genes encoding the same
EP0387380A1 (en) * 1989-03-17 1990-09-19 BEHRINGWERKE Aktiengesellschaft Mutants of urinary plasminogen activator, their production and use
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5332567A (en) 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
NL8902454A (nl) 1989-10-03 1991-05-01 Stichting Centraal Lab Mutanten van de humane plasminogeen activator inhibitor 1 (pai-1), hun bereiding en toepassing, en recombinante polynucleotiden die voor deze mutanten coderende genetische informatie omvatten.
US6271012B1 (en) 1989-10-11 2001-08-07 Genencor International, Inc. Protease muteins and their use in detergents
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0162259B1 (ko) 1989-12-05 1998-12-01 아미 펙터 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
CA2108147C (en) 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
DK0644771T4 (da) 1992-06-11 2006-12-27 Alkermes Inc Lægemiddelsystem til levering af erythropoietin
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
JPH08510250A (ja) 1993-05-17 1996-10-29 イムノメディクス，インコーポレイテッド ビオチンまたはアビジンと金属キレート化タンパク質との複合体による病変の検出および治療法の改善
US5354566A (en) 1993-06-02 1994-10-11 Kraft General Foods, Inc. Preparation of yeast-leavened dough crusts
US5472692A (en) * 1993-07-02 1995-12-05 New England Deaconess Hospital Corporation Pro-urokinase mutants
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
DK1231268T3 (da) 1994-01-31 2005-11-21 Univ Boston Polyklonale antistofbiblioteker
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5686578A (en) 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
WO1996004925A1 (en) 1994-08-12 1996-02-22 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US5766842A (en) 1994-09-16 1998-06-16 Sepracor, Inc. In vitro method for predicting the evolutionary response of a protein to a drug targeted thereagainst
US6168919B1 (en) 1996-07-17 2001-01-02 Diversa Corporation Screening methods for enzymes and enzyme kits
US6077697A (en) 1996-04-10 2000-06-20 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US20040248201A1 (en) 1996-06-27 2004-12-09 Serge Muyldermans Recognition molecules interacting specifically with the active site or cleft of a target molecule
GB9618960D0 (en) 1996-09-11 1996-10-23 Medical Science Sys Inc Proteases
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US20030049678A1 (en) 1999-03-05 2003-03-13 Nienaber Vicki L. Ligand screening and design by X-ray crystallography
DE69933369D1 (en) 1998-04-03 2006-11-09 Compound Therapeutics Inc Adressierbare protein arrays
JP2002523060A (ja) 1998-08-19 2002-07-30 ノボザイムス アクティーゼルスカブ 直接基質再装填による酵素活性スクリーン
CA2362670A1 (en) 1999-03-12 2000-09-14 Georgetown University Matriptase, a serine protease and its applications
CA2373759A1 (en) 1999-05-07 2000-11-16 Human Genome Sciences, Inc. Serine proteases
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
JP2001008687A (ja) 1999-06-25 2001-01-16 Yamanouchi Pharmaceut Co Ltd 新規金属プロテアーゼ及び該金属プロテアーゼ遺伝子
IL142025A0 (en) 1999-07-20 2002-03-10 Morphosys Ag Novel methods for displaying (poly) peptides/proteins on bacteriophage particles via disulfide bonds
AU7476900A (en) 1999-09-09 2001-04-10 Millennium Pharmaceuticals, Inc. 26176, a novel calpain protease and uses thereof
DE19943177C2 (de) 1999-09-09 2002-10-24 Dieter Jenne Verfahren zur Herstellung von aktiven Serienproteasen und inaktiven Varianten
US7030231B1 (en) 1999-09-30 2006-04-18 Catalyst Biosciences, Inc. Membrane type serine protease 1 (MT-SP1) and uses thereof
WO2001032711A2 (en) 1999-10-21 2001-05-10 Board Of Trustees Of The University Of Arkansas Adeno-associated virus aav rep78 major regulatory protein, mutants thereof and uses thereof
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US6797504B1 (en) 2000-09-08 2004-09-28 Dendreon San Diego Llc Inhibitors of serine protease activity of matriptase or MTSP1
EP1252300B1 (en) 2000-02-03 2011-01-19 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
JP4449141B2 (ja) * 2000-02-22 2010-04-14 ソニー株式会社 電源制御装置、電源制御システム
US20020031801A1 (en) 2000-03-24 2002-03-14 Millennium Pharmaceuticals, Inc. 18806, a novel trypsin serine protease-like molecule and uses thereof
US6680178B2 (en) 2000-06-02 2004-01-20 The Regents Of The University Of California Profiling of protease specificity using combinatorial fluorogenic substrate libraries
AU2001266838A1 (en) 2000-06-21 2002-01-02 Georgetown University Inhibitors of matriptase for the treatment of cancer
WO2002008392A2 (en) 2000-07-25 2002-01-31 Bayer Aktiengesellschaft Regulation of human matriptase-like serine protease
US7157596B2 (en) 2000-09-08 2007-01-02 Dendreon Corporation Inhibitors of serine protease activity of matriptase or MTSP1
EP1360490B1 (en) 2001-01-23 2011-12-21 President and Fellows of Harvard College Nucleic-acid programmable protein arrays
WO2002072786A2 (en) 2001-03-13 2002-09-19 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
JP2004535166A (ja) 2001-03-22 2004-11-25 デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー セリンプロテアーゼｃｖｓｐ１４をコードする核酸分子、コードされるポリペプチドおよびそれに基づく方法
EP1379637A4 (en) 2001-03-27 2005-04-06 Dendreon Corp TRANSMEMBRANE SERINE PROTEASE 9 CODING NUCLEIC ACID MOLECULES, THE POLYPEPTIDE CODED, AND METHODS FORMING THEREOF
WO2002092841A2 (en) 2001-05-14 2002-11-21 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
CA2447023A1 (en) 2001-05-23 2002-11-28 Dendreon San Diego Llc Conjugates activated by cell surface proteases and therapeutic uses thereof
EP1390384A4 (en) 2001-05-30 2005-08-17 Chromos Molecular Systems Inc PLATFORMS ON CHROMOSOME BASIS
AU2002315525A1 (en) 2001-07-03 2003-01-21 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 20, the encoded polypeptides and methods based thereon
AU2002330162B2 (en) 2001-10-01 2008-08-07 Takeda Pharmaceutical Company Limited Multi-chain eukaryotic display vectors and uses thereof
US20030143219A1 (en) 2001-10-09 2003-07-31 Madison Edwin L Nucleic acid molecules encoding a transmembrane serine protease 25, the encoded polypeptides and methods based thereon
WO2003044179A2 (en) 2001-11-20 2003-05-30 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
US20030199463A1 (en) 2002-04-23 2003-10-23 Silviu Itescu DNA enzyme to inhibit plasminogen activator inhibitor-1
US20060069035A1 (en) 2002-05-08 2006-03-30 Higazi Abd Al-Roof Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy
EP1361284A1 (en) 2002-05-10 2003-11-12 Direvo Biotech AG Process for generating sequence-specific proteases by directed evolution and use thereof
US20040072276A1 (en) 2002-05-10 2004-04-15 Direvo BioTech AG. Process for generating sequence-specific proteases by directed evolution and use thereof
WO2003104394A2 (en) 2002-05-21 2003-12-18 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 12, the encoded polypeptides and methods based thereon
US20040001801A1 (en) 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
AU2003247776A1 (en) 2002-07-02 2004-01-23 Dendreon Corporation Serine protease 16
US7666627B2 (en) 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
US20060024289A1 (en) 2002-10-02 2006-02-02 Ruggles Sandra W Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
JP5376747B2 (ja) * 2002-10-02 2013-12-25 カタリスト バイオサイエンシーズ， インコーポレイテッド 改変された特異性を有するプロテアーゼを作製する方法およびスクリーニングする方法
US7939304B2 (en) 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
WO2004087933A2 (en) 2003-03-28 2004-10-14 The Regents Of The University Of California A novel encoding method for 'one-bead one-compound' combinatorial libraries
US7070958B2 (en) 2003-04-18 2006-07-04 Thrombolytic Science, Inc. Methods of making pro-urokinase mutants
AU2004249904A1 (en) 2003-06-18 2004-12-29 Direvo Biotech Ag New biological entities and the pharmaceutical or diagnostic use thereof
CA2529659A1 (en) 2003-06-18 2004-12-29 Ulrich Haupts Engineered proteolytic enzyme with altered specificity determining regions
IL156566A0 (en) 2003-06-19 2004-01-04 Hadasit Med Res Service Urokinase plasminogen activator derived octapeptide in the treatment of multiple sclerosis
US7439226B2 (en) 2003-09-30 2008-10-21 The United States Of America As Represented By The Department Of Health And Human Services Serine protease inhibitors
CN103993056A (zh) 2003-10-09 2014-08-20 协和发酵麒麟株式会社 抗凝血酶iii组合物的制造方法
GB0405330D0 (en) * 2004-03-10 2004-04-21 Astrazeneca Ab Enzyme and preparation method
EP2308967B1 (en) 2004-04-12 2017-08-23 Catalyst Biosciences, Inc. Mutant mt-sp1 polypeptides
WO2005100556A2 (en) 2004-04-12 2005-10-27 Catalyst Biosciences Cleavage of vegf and vegf receptor by wild-type and mutant proteases
WO2005123119A2 (en) 2004-06-10 2005-12-29 Catalyst Biosciences, Inc. Administration of neutral endopeptidase to treat inflammatory bowel disease
WO2006067198A2 (en) 2004-12-22 2006-06-29 Direvo Biotech Ag Targeted use of engineered enzymes
EP1726643A1 (en) * 2005-05-27 2006-11-29 Direvo Biotech AG Method for the provision, identification and selection of proteases with altered sensitivity to activity-modulating substances
CN101340928B (zh) 2005-10-21 2011-12-21 催化剂生物科学公司 抑制补体激活的修饰的蛋白酶
CN101374856A (zh) 2005-11-29 2009-02-25 斯克里普斯研究学院 抑制肿瘤细胞浸润、转移和血管生成
TW200804416A (en) 2006-06-19 2008-01-16 Nautilus Technology Llc Modified coagulation factor IX polypeptides and use thereof for treatment
AU2007307260B2 (en) 2006-07-05 2013-02-28 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thereby
AU2008239586B2 (en) 2007-04-13 2013-09-26 Catalyst Biosciences, Inc. Modified factor VII polypetides and uses thereof
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
JP6363600B2 (ja) 2012-07-25 2018-07-25 カタリスト・バイオサイエンシーズ・インコーポレイテッドＣａｔａｌｙｓｔ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 修飾第ｘ因子ポリペプチドおよびその使用

Also Published As

Publication number Publication date
US20120308551A1 (en) 2012-12-06
SG10201503055TA (en) 2015-06-29
AU2007307260A1 (en) 2008-04-17
EP2402438A2 (en) 2012-01-04
TWI369402B (en) 2012-08-01
KR101778174B1 (ko) 2017-09-13
TW200817517A (en) 2008-04-16
JP4922387B2 (ja) 2012-04-25
EP2402437B1 (en) 2016-06-01
ES2372709T3 (es) 2012-01-25
ES2721266T3 (es) 2019-07-30
US8211428B2 (en) 2012-07-03
IL217488A0 (en) 2012-02-29
EP2402438A3 (en) 2012-03-28
IL217488A (en) 2014-02-27
WO2008045148A2 (en) 2008-04-17
CA2656531C (en) 2012-12-11
WO2008045148A8 (en) 2008-09-04
MX2008016221A (es) 2009-02-23
JP4546578B2 (ja) 2010-09-15
ATE530644T1 (de) 2011-11-15
TW201139677A (en) 2011-11-16
KR20140072201A (ko) 2014-06-12
IL217489A0 (en) 2012-02-29
WO2008045148A9 (en) 2008-05-29
JP2012034701A (ja) 2012-02-23
IL196314A0 (en) 2009-09-22
JP2009542218A (ja) 2009-12-03
US9290757B2 (en) 2016-03-22
US20090123452A1 (en) 2009-05-14
HK1165828A1 (zh) 2012-10-12
EP3034607A1 (en) 2016-06-22
NZ596269A (en) 2012-12-21
SG175602A1 (en) 2011-11-28
DK2046951T5 (da) 2012-01-23
CN103289980A (zh) 2013-09-11
HK1226098B (zh) 2017-09-22
CA2656531A1 (en) 2008-04-17
JP2017029167A (ja) 2017-02-09
JP2010075209A (ja) 2010-04-08
EP2046951A2 (en) 2009-04-15
NZ574140A (en) 2012-02-24
HK1126521A1 (en) 2009-09-04
US20130164820A9 (en) 2013-06-27
WO2008045148A3 (en) 2008-10-16
AU2007307260B2 (en) 2013-02-28
IL217489A (en) 2014-02-27
DK2046951T3 (da) 2011-11-28
US20120301945A1 (en) 2012-11-29
KR20150115968A (ko) 2015-10-14
KR20170014023A (ko) 2017-02-07
KR101476458B1 (ko) 2015-01-05
EP2046951B1 (en) 2011-10-26
KR20150033726A (ko) 2015-04-01
EP2402437A3 (en) 2012-03-21
EP3034607B1 (en) 2019-03-27
EP2402437A2 (en) 2012-01-04
US8663633B2 (en) 2014-03-04
JP2015062422A (ja) 2015-04-09
ES2579437T3 (es) 2016-08-11
KR20090031936A (ko) 2009-03-30

Similar Documents

Publication Publication Date Title
HK1226098B (zh) 蛋白酶篩選方法及由此鑒別的蛋白酶
CY1119967T1 (el) Αναστολη πρωτεασης
CY1114916T1 (el) Μεθοδοι
DK2327792T3 (da) Fremgangsmåder og sammensætninger til påvisning af autoimmunsygdomme
DK2314623T3 (da) Il-1 beta-bindende antistoffer og fragmenter deraf
CU20080088A7 (es) Anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de calcitonina
DK1615992T3 (da) Prionproteinbindende materialer og fremgangsmåder til anvendelse
EA200702193A1 (ru) Гликозилирование белков
AR067924A1 (es) Procedimiento de purificacion o de deteccion de una proteina diana
WO2006135793A3 (en) Protein engineering with analogous contact environments
CR9637A (es) Proteinas de enlace il-6
EP2166110A4 (en) SCREENING PROCEDURE USING THE NEW EPHA4 SUBSTRATE FOR GAMMA SECRETASE
DE602006018424D1 (de) Peptide zum nachweis von ehrlichia ewingii antikörper
AR054146A1 (es) Anticuerpos monoclonales, lineas de celulas de hibridomas metodos y conjuntos de elementos para detectar fitasa
DK1987357T3 (da) Polypeptider, som genkendes af anti-Trichinella-antistoffer, og anvendelser deraf
NO20064715L (no) Deteksjon, isolering og anvendelse av renalase (monoamin aksidase C)
UA101142C2 (ru) Способ разработки антитела
WO2006079334A3 (de) Verfahren zu nachweis und quantifizierung von proteinen unter verwendung von farbstoffen auf der basis von polymethinen
ATE416262T1 (de) Einen grössenausschlussschritt verwendendes verbessertes bisulfit-verfahren
NO20053990L (no) Assay for proteinisoformer
ATE498018T1 (de) Nachweis von salmonella-lactose+
ATE457841T1 (de) Antrieb
WO2007100807A8 (en) Npc1l1 orthologues
NO20074880L (no) Proteaseinhibitor forloper syntese
DE502006005985D1 (de) Testsystem zum nachweis von salmonellen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application